Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05486000

To Assess the Safety and Efficacy of the Atrial Shunt Implant System in the Treatment of Patients With Chronic Left Heart Failure

Sponsor: Morningside (Nantong) Medical Co.,Ltd

View on ClinicalTrials.gov

Summary

This trial is a prospective, multicenter, single-group target-value clinical trial in which patients with chronic left heart failure are planned to be recruited. Using the atrial shunt implantation system developed and produced by Morningside (Nantong) Medical Device Co., Ltd., the atrial septum is used to implant the instruments in the atrial septum. to verify the safety and efficacy of the atrial shunt implant system for the treatment of patients with chronic left heart failure.

Official title: Evaluating the Safety and Efficacy of Atrial Shunt Implantation Systems for the Treatment of Patients With Chronic Left Heart Failure Prospective, Multicenter, Single-group Target Value Clinical Trials

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2022-08

Completion Date

2026-10

Last Updated

2022-08-03

Healthy Volunteers

Yes

Conditions

Left Heart Failure

Interventions

DEVICE

Atrial shunt implant system

Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the "Atrial Shunt Implant System"

Inclusion Criteria: 1. Age ≥ 18 years; 2. Consistently stable GDMT (Guidelines for Guiding Drugs) according to The Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018 Treatment) heart failure for patients with chronic left heart failure who are still symptomatic for at least 1 month; 3. History of hospital admission to heart failure in the past 12 months, serum BNP or NT-proBNP liters" within 6 months High (BNP in sinus rhythm patients\> 70 pg/ml, atrial fibrillation patients \> 200 pg/ml, or sinus rhythm patients NT-proBNP"\> 200 pg/ml, patients with atrial fibrillation \>600 pg/ml); 4. Cardiac catheterization measures resting mean lung capillary wedge pressure PCWP or left atrial pressure LAP≥15 mmHg,And the difference between the RAP order of pulmonary capillary wedge pressure PCWP and right atrial pressure is ≥ 5 mmHg； 5. Cardiac Function Classification (NYHA) Grade II-IV; 6. The patient or his/her guardian can understand the purpose of the study, voluntarily participate and sign a written informed consent form, which is acceptable Patients followed up； - Exclusion Criteria: 1. Primary organic valvular disease and severe coronary artery disease requiring revascularization that are currently indicated for surgical intervention Changes, heart-related diseases indicated for pacemaker implantation treatment; 2. Pulmonary hypertension (pulmonary vascular resistance PVR\>4WoodsUnits); 3. History of myocardial infarction or heart treatment surgery within three months; 4. Patients with infective endocarditis or ultrasound findings of thrombosis or vegetations in the heart; 5. Anatomical abnormalities that make surgery unfinished or anatomically unsuitable for surgery; 6. Life expectancy \< 12 months; 7. History of stroke, transient cerebral ischemia, deep vein thrombosis or pulmonary embolism in the past 6 months; 8. Pregnant or lactating women, or persons with family planning in the next year; 9. Subjects whose judgement of poor compliance and who were unable to complete the study as required; -

Locations (1)